BBS-Bioactive Bone Substitutes Plc | Company Release | April 15, 2024 at 08:00:00 EEST

BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort Global Opportunities PCC Ltd

BBS-Bioactive Bone Substitutes Plc ("BBS") has received two new requests from Riverfort Global Opportunities PCC Ltd ("Riverfort") to convert convertible notes into Company shares.

  • 11 March 2024: A request to convert a proportion of EUR 54,202 of the convertible notes at a conversion price of EUR 0.44784 per share. The conversion shall be executed by transferring a total of 121,030 treasury shares to Riverfort.
  • 9 April 2024: A request to convert a proportion of EUR 80,000 of the convertible notes at a conversion price of EUR 0.40527 per share. The conversion shall be executed by transferring a total of 197,399 treasury shares to Riverfort.

In both conversions, the conversion price according to the terms and conditions is “90% of the lowest volume weighted average price of a trading day during ten trading days before the applicable subscription notice“.

After the transfers, the Company will hold a total of 606,656 treasury shares in its possession.

For more information, please contact:
Juliusz Rakowski, CEO
+358 50 448 5132
juliusz.rakowski@bbs-artebone.fi

Certified Advisor:
Nordic Certified Adviser AB,
+46 70 551 67 29,
info@certifiedadviser.se

Distribution
Nasdaq Helsinki
https://www.bbs-artebone.fi/

BBS in brief
BBS -Bioactive Bone Substitutes Plc is an orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our first developed product, ARTEBONE® Paste, is in the final stages of the CE marking process to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ over 20 people.

BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.

More information: www.bbs-artebone.fi

Attachments
BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort Global Opportunities PCC Ltd

© Modular Finance, source Nordic Press Releases